Clarity Pharmaceuticals Ltd

ASX (AUD): Clarity Pharmaceuticals Ltd (CU6)

Last Price

4.22

Today's Change

+0.07 (1.68%)

Day's Change

4.019 - 4.31

Trading Volume

1,831,270

Overview

Market Cap

1 Billion

Shares Outstanding

320 Million

Avg Volume

1,629,509

Avg Price (50 Days)

5.55

Avg Price (200 Days)

5.60

PE Ratio

-28.13

EPS

-0.15

Earnings Announcement

26-Feb-2025

Previous Close

4.15

Open

4.09

Day's Range

4.02 - 4.31

Year Range

2.12 - 8.975

Trading Volume

1,831,270

Price Change Highlight

1 Day Change

1.69%

5 Day Change

2.93%

1 Month Change

-23.55%

3 Month Change

-44.98%

6 Month Change

-17.58%

Ytd Change

3.94%

1 Year Change

101.91%

3 Year Change

417.79%

5 Year Change

181.33%

10 Year Change

181.33%

Max Change

181.33%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment